Apotex Moves To Block Coherus' Neulasta Biosimilar; Asks FDA To Require Patient Studies

Apotex argues that biosimilar studies in healthy volunteers are not sufficient to show clinically meaningful differences with the reference product; Coherus says it believes its application is scientifically sound.